bioAffinity Technologies Net Income
| BIAF Stock | USD 1.10 0.11 11.11% |
As of the 12th of February 2026, BioAffinity Technologies shows the Coefficient Of Variation of (919.82), risk adjusted performance of (0.08), and Standard Deviation of 6.65. bioAffinity Technologies technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm bioAffinity Technologies treynor ratio, as well as the relationship between the value at risk and skewness to decide if bioAffinity Technologies is priced correctly, providing market reflects its regular price of 1.1 per share. Given that BioAffinity Technologies is a hitting penny stock territory we recommend to closely look at its jensen alpha.
BioAffinity Technologies Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 1.1383 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -8.1 M | -8.5 M | |
| Net Loss | -8.1 M | -8.5 M | |
| Net Loss | -7.3 M | -7.6 M | |
| Net Loss | (25.71) | (27.00) | |
| Net Income Per E B T | 0.90 | 0.80 |
BioAffinity | Net Income | Build AI portfolio with BioAffinity Stock |
The Net Income trend for bioAffinity Technologies offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether BioAffinity Technologies is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest BioAffinity Technologies' Net Income Growth Pattern
Below is the plot of the Net Income of bioAffinity Technologies over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in bioAffinity Technologies financial statement analysis. It represents the amount of money remaining after all of bioAffinity Technologies operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is BioAffinity Technologies' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioAffinity Technologies' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (9.04 M) | 10 Years Trend |
|
Net Income |
| Timeline |
BioAffinity Net Income Regression Statistics
| Arithmetic Mean | (5,204,709) | |
| Coefficient Of Variation | (46.10) | |
| Mean Deviation | 2,232,012 | |
| Median | (3,307,499) | |
| Standard Deviation | 2,399,501 | |
| Sample Variance | 5.8T | |
| Range | 5.7M | |
| R-Value | (0.87) | |
| Mean Square Error | 1.4T | |
| R-Squared | 0.77 | |
| Slope | (415,662) | |
| Total Sum of Squares | 92.1T |
BioAffinity Net Income History
Other Fundumenentals of bioAffinity Technologies
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
BioAffinity Technologies Net Income component correlations
BioAffinity Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for BioAffinity Technologies is extremely important. It helps to project a fair market value of BioAffinity Stock properly, considering its historical fundamentals such as Net Income. Since BioAffinity Technologies' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BioAffinity Technologies' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BioAffinity Technologies' interrelated accounts and indicators.
Click cells to compare fundamentals
Can Biotechnology industry sustain growth momentum? Does BioAffinity have expansion opportunities? Factors like these will boost the valuation of BioAffinity Technologies. Projected growth potential of BioAffinity fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating BioAffinity Technologies demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (13.53) | Revenue Per Share | Quarterly Revenue Growth (0.39) | Return On Assets | Return On Equity |
The market value of bioAffinity Technologies is measured differently than its book value, which is the value of BioAffinity that is recorded on the company's balance sheet. Investors also form their own opinion of BioAffinity Technologies' value that differs from its market value or its book value, called intrinsic value, which is BioAffinity Technologies' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because BioAffinity Technologies' market value can be influenced by many factors that don't directly affect BioAffinity Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between BioAffinity Technologies' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding BioAffinity Technologies should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, BioAffinity Technologies' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
BioAffinity Technologies 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to BioAffinity Technologies' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of BioAffinity Technologies.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in BioAffinity Technologies on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding bioAffinity Technologies or generate 0.0% return on investment in BioAffinity Technologies over 90 days. BioAffinity Technologies is related to or competes with Artelo Biosciences, GT Biopharma, Mobile Health, WORK Medical, Psyence Biomedical, Revelation Biosciences, and Protagenic Therapeutics. bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targete... More
BioAffinity Technologies Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure BioAffinity Technologies' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess bioAffinity Technologies upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.12) | |||
| Maximum Drawdown | 32.32 | |||
| Value At Risk | (12.79) | |||
| Potential Upside | 11.4 |
BioAffinity Technologies Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioAffinity Technologies' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as BioAffinity Technologies' standard deviation. In reality, there are many statistical measures that can use BioAffinity Technologies historical prices to predict the future BioAffinity Technologies' volatility.| Risk Adjusted Performance | (0.08) | |||
| Jensen Alpha | (1.01) | |||
| Total Risk Alpha | (1.31) | |||
| Treynor Ratio | (0.19) |
BioAffinity Technologies February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | (0.18) | |||
| Mean Deviation | 4.95 | |||
| Coefficient Of Variation | (919.82) | |||
| Standard Deviation | 6.65 | |||
| Variance | 44.23 | |||
| Information Ratio | (0.12) | |||
| Jensen Alpha | (1.01) | |||
| Total Risk Alpha | (1.31) | |||
| Treynor Ratio | (0.19) | |||
| Maximum Drawdown | 32.32 | |||
| Value At Risk | (12.79) | |||
| Potential Upside | 11.4 | |||
| Skewness | (0.22) | |||
| Kurtosis | 0.6679 |
bioAffinity Technologies Backtested Returns
bioAffinity Technologies secures Sharpe Ratio (or Efficiency) of -0.0912, which signifies that the company had a -0.0912 % return per unit of risk over the last 3 months. bioAffinity Technologies exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm BioAffinity Technologies' Coefficient Of Variation of (919.82), risk adjusted performance of (0.08), and Standard Deviation of 6.65 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 3.86, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, BioAffinity Technologies will likely underperform. At this point, bioAffinity Technologies has a negative expected return of -0.61%. Please make sure to confirm BioAffinity Technologies' total risk alpha, skewness, rate of daily change, as well as the relationship between the maximum drawdown and accumulation distribution , to decide if bioAffinity Technologies performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.69 |
Good predictability
bioAffinity Technologies has good predictability. Overlapping area represents the amount of predictability between BioAffinity Technologies time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of bioAffinity Technologies price movement. The serial correlation of 0.69 indicates that around 69.0% of current BioAffinity Technologies price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.69 | |
| Spearman Rank Test | 0.44 | |
| Residual Average | 0.0 | |
| Price Variance | 0.03 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
BioAffinity Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, bioAffinity Technologies reported net income of (9.04 Million). This is 102.65% lower than that of the Biotechnology sector and 105.22% lower than that of the Health Care industry. The net income for all United States stocks is 101.58% higher than that of the company.
BioAffinity Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioAffinity Technologies' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioAffinity Technologies could also be used in its relative valuation, which is a method of valuing BioAffinity Technologies by comparing valuation metrics of similar companies.BioAffinity Technologies is currently under evaluation in net income category among its peers.
BioAffinity Technologies Institutional Holders
Institutional Holdings refers to the ownership stake in BioAffinity Technologies that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of BioAffinity Technologies' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing BioAffinity Technologies' value.| Shares | Sprott Inc. | 2025-06-30 | 10 K | Tower Research Capital Llc | 2025-06-30 | 3.1 K | Citigroup Inc | 2025-06-30 | 1.5 K | Bank Of America Corp | 2025-06-30 | 205 | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 100.0 | Ubs Group Ag | 2025-06-30 | 24.0 | Warberg Asset Management Llc | 2025-06-30 | 0.0 | Barclays Plc | 2025-06-30 | 0.0 | Citadel Advisors Llc | 2025-03-31 | 0.0 | Geode Capital Management, Llc | 2025-06-30 | 125.5 K | Hanson Mcclain Inc | 2025-06-30 | 53.7 K |
BioAffinity Fundamentals
| Return On Equity | -2.45 | ||||
| Return On Asset | -0.72 | ||||
| Profit Margin | (2.17) % | ||||
| Operating Margin | (1.59) % | ||||
| Current Valuation | (2.52 M) | ||||
| Shares Outstanding | 4.5 M | ||||
| Shares Owned By Insiders | 3.15 % | ||||
| Shares Owned By Institutions | 9.20 % | ||||
| Number Of Shares Shorted | 39.71 K | ||||
| Price To Book | 0.50 X | ||||
| Price To Sales | 0.66 X | ||||
| Revenue | 9.36 M | ||||
| Gross Profit | 1.89 M | ||||
| EBITDA | (8.33 M) | ||||
| Net Income | (9.04 M) | ||||
| Cash And Equivalents | 214.4 K | ||||
| Cash Per Share | 0.08 X | ||||
| Total Debt | 1.5 M | ||||
| Current Ratio | 0.02 X | ||||
| Book Value Per Share | 2.57 X | ||||
| Cash Flow From Operations | (7.26 M) | ||||
| Short Ratio | 0.55 X | ||||
| Earnings Per Share | (13.53) X | ||||
| Target Price | 6.0 | ||||
| Number Of Employees | 57 | ||||
| Beta | 2.46 | ||||
| Market Capitalization | 4.47 M | ||||
| Total Asset | 6.51 M | ||||
| Retained Earnings | (53.64 M) | ||||
| Working Capital | (409.81 K) | ||||
| Net Asset | 6.51 M |
About BioAffinity Technologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze bioAffinity Technologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioAffinity Technologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of bioAffinity Technologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out For more detail on how to invest in BioAffinity Stock please use our How to Invest in BioAffinity Technologies guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Can Biotechnology industry sustain growth momentum? Does BioAffinity have expansion opportunities? Factors like these will boost the valuation of BioAffinity Technologies. Projected growth potential of BioAffinity fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating BioAffinity Technologies demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (13.53) | Revenue Per Share | Quarterly Revenue Growth (0.39) | Return On Assets | Return On Equity |
The market value of bioAffinity Technologies is measured differently than its book value, which is the value of BioAffinity that is recorded on the company's balance sheet. Investors also form their own opinion of BioAffinity Technologies' value that differs from its market value or its book value, called intrinsic value, which is BioAffinity Technologies' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because BioAffinity Technologies' market value can be influenced by many factors that don't directly affect BioAffinity Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between BioAffinity Technologies' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding BioAffinity Technologies should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, BioAffinity Technologies' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.